Use of the dopamine agonist cabergoline in the treatment of movement disorders

REFERENCES

• OLANOW CW, WATTS RL, KOLLER WC: An algorithm (decision tree) for the management of Parkinson's disease (200 1) :treatment guidelines. Neurology (2001) 56\(Suppl. 5):S1–588.
   Google Scholar
• BRECHT HM: A comparison of dopamine agonists. Aktuel Neurol (1998) 25:S310–S316.
   Web of Science ®Google Scholar
• CHAUDHURI KR, APPIAH-KUBI LS, TRENKWALDER C: Restless leg syndrome. Neurol. Neurosurg. Psych. (2001) 71(2):143–146.
   PubMed Web of Science ®Google Scholar
• PARKINSON STUDY GROUP: Dopamine transporter brain imaging to assess the effects of pramipexole versus levodopa on Parkinson's disease progression. JA/VIA (2002) 287(13):1653–1661.
   Google Scholar
• WHONE AL, ORSAY PR, DAVIS Metal.: The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with L-dopa. Neurology (2002) 58\(Suppl. 3):A82.
   Google Scholar
• ARAI N, ISAJI M, MIYATA H et al: Differential effects of three dopamine receptor agonists in MPTP-treated mon-keys. J. Neurd. Transm. (1995) 10:55–62.
   Web of Science ®Google Scholar
• KOSHIMURA K, TANAKA J, MURAKAMI Y, KATO Y: Effects of dopamine and L-DOPA on survival of PC12 cells. J. Neurtisci. Res. (2000) 62(1):112–119.
   PubMed Web of Science ®Google Scholar
• SANDER J, DENGLER R, ODIN P: Neuroprotective effects of the dopamine agonist cabergoline in the rat 6-0HDA Parkinson model, preclinical data on dopamine agonists. In: Focus on Medicine No. 14. Chase T & Bedard P (Eds), Black-well Science, Oxford, UK (1999):7–13.
   Google Scholar
• LEWD, JANKOVIC J: Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging (2001) 18:389–396.
   PubMed Web of Science ®Google Scholar
• SAWADA H et al.: Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann. Neurol. (1998) 44:110–119.
   PubMed Web of Science ®Google Scholar
• OLANOW CW, JENNER P, BROOKS DJ: Dopamine agonists and neuroprotection in Parkinson's disease. Ann. Neurol. (1998) 44\(Suppl. 1):167–174.
   Google Scholar
• FARIELLO RG: Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease, Drugs (1998) 55\(Suppl. 1):10–16.
   Google Scholar
• WISEMAN LR, FITTON A: Cabergoline. A review of its efficacy in the treatment of Parkinson's disease. CNS Drugs (1999) 12(6):485–497.
   Google Scholar
• CHASE TN: The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs (1998) 55\(Suppl. 1):1–9.
   Google Scholar
• CHASE TN, BARONTI F, FABBRINI G, HEUSER IJ, JUNCOS JL, MOURADIAN MML: Rationale for continuous dopamino-mimetic therapy of Parkinson's disease. Neurology (1989) 39\(Suppl. 2):7–10.
   Google Scholar
• PAPA SM, ENGBER TM, KASK AM, CHASE TN: Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. (1994) 662:69–74.
   PubMed Web of Science ®Google Scholar
• BRAVI D, MOURADIAN MM, ROBERTS JW, DAVIS TL, SOHN YH, CHASE TN: Wearing off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann. Neurol. (1994) 36:27–31.
   PubMed Web of Science ®Google Scholar
• OH JD, VAUGHAN CL, CHASE TN: Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA/receptor subunits. Brain Res. (1999) 821:433–442.
   PubMed Web of Science ®Google Scholar
• OH JD, DEL DOTTO P, CHASE TN: Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. NeuroscL Lett. (1997) 228:5–8.
   PubMed Web of Science ®Google Scholar
• DOUCET JP, NAKABEPPU Y, BEDARD PJ et al.: Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur.j Neurosci. (1996) 8(2):365–381.
   PubMed Web of Science ®Google Scholar
• HAGELL P, ODIN P: Apomorphine in the treatment of Parkinson's disease. J. NeuroscL Nursing (2001) 33:21–38.
   PubMedGoogle Scholar
• REUTER I, ELLIS CM, CHAUDHURI K: Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurologica Scandinavica (1999) 100(3):163–167.
   PubMed Web of Science ®Google Scholar
• ARNULF I, BEJJANI BP, GARMA L et al.: Improvement of sleep architecture with subthalamic nuclear stimulation. Neurology (2001) 55:1732–1734.
   Web of Science ®Google Scholar
• CALABRESE VP, LLOYD KA, BRANCAZIO P et al: N-0923, a novel soluble dopamine agonist in the treatment of parkinsonism. Mov. Disord. (1998) 13:768–774.
   PubMed Web of Science ®Google Scholar
• ARAI N, ISAJI M, KOJIMA M, MIZUTA E, KUNO S: Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys. J. Neural. Transm. (1996) 103(11):1307–1316.
   PubMed Web of Science ®Google Scholar
• OLANOW CW, TATTON WG: Etiology and pathogenesis of Parkinson's disease. Ann. Rev Neurosci (1999) 22:123–144.
   PubMed Web of Science ®Google Scholar
• PEDERSEN V, DOUBLE K, SCHMIDT WJ, RIEDERER P, GERLACH M: Effect of cabergoline and lisuride on motor behaviour and dopamine receptor binding in 6-0HDA-lesioned rats. J. Neural. Transm. (1999) 106(1). Abstract.
   Google Scholar
• CLARKE CE, DEANE KH: Cabergoline for levodopa-induced complications in Parkinson's disease. J. Neurol (2000) 247\(Suppl. 4):17–19.
   Google Scholar
• STEIGER MJ, EL DEBAS T, ANDERSON T, FINDLEY LJ, MARSDEN CD: Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. Neurol (1996) 243(1):68–72.
   Web of Science ®Google Scholar
• HUTTON JT, KOLLER WC, AHLSKOG JE et al.: Multicentre placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology (1996) 46:1062–1065.
   PubMed Web of Science ®Google Scholar
• CLARKE CE, DEANE KD: Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst. Rev (2001) (1):CD001518.
   Google Scholar
• GERSHANIK 0, DOM R, TICHYJ et al: Multicentre multinational double-blind study of the activity and tolerability of cabergoline versus bromocriptine in parkinsonian patients suffering from L-dopa associated motor complications, not on treatment with dopamine agonist agents. Pharmacia & Upjohn, Peapack, NJ, FCE report 21336/739i (1994).
   Google Scholar
• INZELBERG R et al: Double blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology (1996) 47(3):785–788.
   PubMed Web of Science ®Google Scholar
• RINNE UK, BRACCO F, CHOUZA C et al.: Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs (1998) 55\(Suppl. 1):23–30.
   Google Scholar
• RASCOL 0, BROOKS DJ, KORCZYN AD, DE DEYN PP, CLARKE CE, LANG AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl. J. Med. (2000) 342(20):1484–1491.
   Google Scholar
• MARSDEN CD: Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa. Drugs (1998) 55\(Suppl. 1):17–22.
   Google Scholar
• MUSCH B: The long-acting dopamine agonist cabergoline in the treatment of early Parkinson's disease. 5th International Conference on Progress in Alzheimer. Kyoto, Japan (2001). Abstract 117.
   Google Scholar
• PARKINSON STUDY GROUP G: Pramipexole versus levodopa as initial traetment for Parkinson's disease - a randomized controlled trial. JAMA (2000) 284:1931–1938.
   PubMed Web of Science ®Google Scholar
• APPIAH-KUBI L, NISBET A, BURN DJ, CHAUDHURI KR: Cabergoline monotherapy in clinical practice: a two-year observational study in young and elderly PD patients. Presented to the Association of British Neurologists, Oxford, April 2002., INNP (2002). In Press.
   Google Scholar
• REUTER I, CHAUDHURI K: The management of nocturnal disabilities in Parkinson's disease. NAFP Official Yearbook and Annual Review Scorpio Publishing (1998):311–314.
   Google Scholar
• CHAUDHURI K, BHATTACHARYA K, AGAPITO C, PORTER MC, MILLS J, CLOUGH C: The use of cabergoline in nocturnal parkinsonian disabilities causing sleep disruption: a parallel study with controlled-release levodopa. Eur: .1. Neurol (1999) 6(Suppl.):S11–S15.
   Google Scholar
• GHATANI T, AGAPITO C, BHATTACHARYA K, CLOUGH C, CHAUDHURI K: Comparative audit of pergolide and cabergoline therapy in the treatment of nocturnal 'off' periods causing sleep disruption in Parkinson's disease. Eur: .1. Neurol (2001) 8\(Suppl. 1):8–11.
   Google Scholar
• ULM G, SCHULER P for the MODAC STUDY GROUP: Cabergoline versus Pergolide a video-blinded, randomised, multicentre cross-over study. Akt. Neurologic.. (1999) 25:360–365.
   Google Scholar
• KATAYAMA S, MIYAMOTO T, TATSUMOTO M, WATANABE K: Averaging actigraphic analysis of diurnal motor fluctuations during dopamine agonist therapy. International Congress of European Federation of Neurological Societies Copenhagen, Denmark. Eur: .1. Neurol (2000) 7\(Suppl. 3):575. Abstract.
   Google Scholar
• SHULMAN LM, MINAGAR A, RABINSTEIN A, WEINER WJ: The use of dopamine agonists in very elderly patients with Parkinson's disease. Mov. Disord. (2000) 15(4):664–668.
   PubMed Web of Science ®Google Scholar
• APPIAH-KUBI L, FORBES A, GUNAWARDENA D, CHAUDHURI K: The tolerability and efficacy of sustained dopaminergic therapy using cabergoline mono or adjunctive therapy in 202 elderly and young PD patients: a two year clinical observational study. International Congress of Parkinson's disease, Helsinki, Finland. Park. Relat. Disoid. (2001) 7:S28. Abstract P-MO–74.
   Google Scholar
• HENING W, ALLEN R, EARLEY C, KUSHIDA C, PICCHIETI D, SILBER M: The treatment of restless legs syndrome and periodic limb movement disorder. Sleep (1999) 22(7):970–999.
   PubMed Web of Science ®Google Scholar
• STIASNY K, WETTER TC, TRENKWALDER C, OERTEL WH: Restless legs syndrome and its treatment by dopamine agonists. Park. Relat. Disord. (2000) 7(Suppl. A):21–25.
   Google Scholar
• STIASNY K, ROBBECKE J, SCHULER P,OERTEL WH: Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline - an open clinical trial. Sleep (2000) 23(Suppl. B, 3):349–354.
   Google Scholar
• HAAKE P, EXTON MS, HAVERKAMP J et al.: Absence of orgasm-induced prolactin secretion in a healthy multi-orgasmic male subject. Intl Impot. Res. (2002) 14:133–135.
   PubMed Web of Science ®Google Scholar
• FRUCHT S, ROGER JD, GREENE PE et al.: Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology (1999) 52:1908–1910.
   PubMed Web of Science ®Google Scholar
• OLANOW CW, SCHAPIRA AH, ROTH T: Waking up to sleep episodes in Parkinson's disease. Mov. Disoid. (2000) 15:212–215.
   PubMed Web of Science ®Google Scholar
• NISHINO S, RIPLEY B, OVEREEM S, LAMMERS GL, MIGNOT E: Hypocretin (orexin) deficiency in human narcolepsy. Lancet (2000) 355:39–40.
   PubMed Web of Science ®Google Scholar
• PAL S, BHATTACHARYA KF, AGAPITO C, CHAUDHURI K: A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J. Neural. Transm. (2001) 108(1):71–77.
   PubMed Web of Science ®Google Scholar